Amy Gotvaslee
Family · Bismarck, NDNPI 1396157830
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 303 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 15.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,298, 2.4 times the $542 reported in 2021. Among family clinicians in ND with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 303 payments — averaging $13.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$645
- Amgen$604
- Lilly USA, LLC$379
- Novo Nordisk$372
- Pfizer$280
- Dexcom, Inc.$270
- plus $2K from 29 others
What the payments were for
- Food & beverage$4,125100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 51 | $645 |
| Amgen | 49 | $604 |
| Lilly USA, LLC | 32 | $379 |
| Novo Nordisk | 48 | $372 |
| Pfizer | 21 | $280 |
| Dexcom, Inc. | 15 | $270 |
| Astellas Pharma US Inc | 12 | $225 |
| Boehringer Ingelheim | 13 | $221 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $158 |
| AstraZeneca | 4 | $153 |
| Novartis | 9 | $150 |
| E.r. Squibb & Sons, L.L.C. | 5 | $97 |
| Phathom Pharmaceuticals, Inc. | 5 | $56 |
| Merck | 3 | $51 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $42 |
| Johnson & Johnson(3 entities) | 3 | $42 |
| Daiichi Sankyo Inc. | 2 | $40 |
| Madrigal Pharmaceuticals | 1 | $29 |
| GSK | 2 | $29 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $27 |
| Lexicon Pharmaceuticals, Inc. | 2 | $26 |
| Axsome Therapeutics, Inc. | 1 | $25 |
| Aimmune Therapeutics, Inc. | 1 | $23 |
| Medtronic | 1 | $20 |
| Lundbeck LLC | 1 | $19 |
| Regeneron Healthcare Solutions, Inc. | 1 | $18 |
| Biogen | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| Ardelyx, Inc. | 1 | $15 |
| Exact Sciences | 1 | $14 |
| Phadia US Inc. | 1 | $13 |
| Xeris Pharmaceuticals, Inc. | 1 | $13 |
| Amarin Pharma, Inc. | 1 | $13 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
| Biohaven Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$114
How this compares
$4,125 in reported general payments places this provider in the 95th percentile of 496 family providers in North Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 55 | $62,933 |
| JardianceEmpagliflozin | 60 | $50,227 |
| EliquisApixaban | 25 | $27,275 |
| FarxigaDapagliflozin Propanediol | 31 | $23,287 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 11 | $12,782 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 15 | $4,491 |
| Levothyroxine Sodium | 272 | $3,747 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 33 | $3,624 |
| Rosuvastatin Calcium | 194 | $3,342 |
| Novolog FlexpenInsulin Aspart | 13 | $2,699 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 13 | $2,244 |
| Bupropion XlBupropion Hcl | 47 | $2,175 |
| Fluoxetine Hcl | 69 | $2,064 |
| Atorvastatin Calcium | 167 | $1,927 |
| Metoprolol Succinate | 95 | $1,711 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $372 | $62,93355 claims |
| Boehringer IngelheimJardiance | $221 | $50,22760 claims |
| PfizerEliquis, Abrysvo | $280 | $31,76640 claims |
| AstraZenecaFarxiga | $153 | $23,28731 claims |
| MerckJanumet Xr | $51 | $12,78211 claims |
| AbbVieSynthroid | $645 | $1,32514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 496 family providers in North Dakota.
Other family in Bismarck
- Courtney WoodburyBismarck$8K
- Monica GoetzBismarck$8K
- Elizabeth ScheurerBismarck$6K
- Kayla HolzerBismarck$5K
- Amanda AllmarasBismarck$5K
- Kathryn StensgardBismarck$5K
- Sally FrankBismarck$4K
- Michelle MaierBismarck$4K
- Tanya GuthmillerBismarck$4K
- Amanda HelmBismarck$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.